Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human blood-brain barrier

Xenobiotica

Volumn 42, Issue 9, 2012, Pages 880-890

  Cheng, Ziqiang ^a   Liu, Houfu ^a   Yu, Na ^b   Wang, Fei ^a   An, Gang ^a   Xu, Yan ^a   Liu, Qian ^a   Guan, Chen Bing ^a   Ayrton, Andrew ^a  

^a GLAXOSMITHKLINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

blood brain barrier; OATP1A2; triptans; uptake transporter

Indexed keywords

ALMOTRIPTAN; AMINE; AURANTIIN; ELETRIPTAN; FEXOFENADINE; FROVATRIPTAN; GRANISETRON; MEMBRANE PROTEIN; MESORIDAZINE; METOCLOPRAMIDE; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1A2; RIZATRIPTAN; SEROTONIN 1B AGONIST; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ARTICLE; BLOOD BRAIN BARRIER; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; BACULOVIRIDAE; BLOOD-BRAIN BARRIER; DOGS; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MADIN DARBY CANINE KIDNEY CELLS; MIGRAINE DISORDERS; ORGANIC ANION TRANSPORTERS; REAL-TIME POLYMERASE CHAIN REACTION; SEROTONIN 5-HT1 RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTAMINES;

EID: 84864970227     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.675455     Document Type: Article

References (29)

1. Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, Burchard EG, Giacomini KM. (2006). Interaction of methotrexate with organicanion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 318:521-529.
2. Bergström M, Yates R, Wall A, Kågedal M, Syvänen S, Långström B. (2006). Blood-brain barrier penetration of zolmitriptan-modelling of positron emission tomography data. J Pharmacokinet Pharmacodyn 33:75-91.
3. Braggio S, Montanari D, Rossi T, Ratti E. (2010). Drug efficiency: A new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 5:609-618.
4. Bronger H, König J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, Nies AT. (2005). ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65:11419-11428.
5. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
6. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. (2008). Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36:995-1002.
7. Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R. (2003). Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 31:861-869.
8. Franke RM, Scherkenbach LA, Sparreboom A. (2009). Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 10:339-344.
9. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ. (2000). Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 294:73-79.
10. Gao B, Stieger B, Noé B, Fritschy JM, Meier PJ. (1999). Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-1264.
11. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, Kim RB. (2007). Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 81:362-370.
12. Hassan NJ, Pountney DJ, Ellis C, Mossakowska DE. (2006). BacMam recombinant baculovirus in transporter expression: A study of BCRP and OATP1B1. Protein Expr Purif 47:591-598.
13. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek- Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
14. Kalliokoski A, Niemi M. (2009). Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158:693-705.
15. Kim HJ, Triplett BA. (2004). Characterization of GhRac1 GTPase expressed in developing cotton (Gossypium hirsutum L.) fibers. Biochim Biophys Acta 1679:214-221.
16. Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF, Wolkoff AW, Meier PJ. (1995). Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109:1274-1282.
17. Kusuhara H, Sugiyama Y. (2005). Active efflux across the blood-brain barrier: Role of the solute carrier family. NeuroRx 2:73-85.
18. Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, Leake BF, Kim RB. (2005). Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): Implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280:9610-9617.
19. Mandery K, Bujok K, Schmidt I, Keiser M, Siegmund W, Balk B, König J, Fromm MF, Glaeser H. (2010). Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol 80:1746-1753.
20. Moriyama Y, Hiasa M, Matsumoto T, Omote H. (2008). Multidrug and toxic compound extrusion (MATE)-type proteins as anchor transporters for the excretion of metabolic waste products and xenobiotics. Xenobiotica 38:1107-1118.
21. Ose A, Kusuhara H, Endo C, Tohyama K, Miyajima M, Kitamura S, Sugiyama Y. (2010). Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos 38:168-176.
22. Pardridge WM. (2005). The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2:3-14.
23. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab Dispos 34:786-792.
24. Sakai Y, Dobson C, Diksic M, Aubé M, Hamel E. (2008). Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 70:431-439.
25. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. (2007). Central nervous system drug disposition: The relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205-213.
26. Tfelt-Hansen PC. (2010). Does sumatriptan cross the blood-brain barrier in animals and man? J Headache Pain 11:5-12.
27. Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ. (2005). Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 288:349-359.
28. Wang Y, Wu Z, Li D, Wang D, Wang X, Feng X, Xia M. (2011). Involvement of oxygen-regulated protein 150 in AMP-activated protein kinase-mediated alleviation of lipid-induced endoplasmic reticulum stress. J Biol Chem 286:11119-11131.
29. Zhou L, Schmidt K, Nelson FR, Zelesky V, Troutman MD, Feng B. (2009). The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl- 2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab Dispos 37:946-955.